Bluefin Capital Management LLC Purchases New Shares in Pfizer Inc. $PFE

Key Points

• Bluefin Capital Management LLC has acquired a new position in Pfizer Inc. worth approximately $441,000 by purchasing 17,400 shares during the first quarter.
• Pfizer reported **better-than-expected quarterly earnings**, with a net revenue of $14.65 billion and an EPS of $0.78, surpassing estimates.
• The company declared a quarterly dividend of $0.43 per share, yielding 7.0%, with a dividend payout ratio currently at 91.49%.

Bluefin Capital Management LLC acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,400 shares of the biopharmaceutical company's stock, valued at approximately $441,000.

Several other institutional investors have also bought and sold shares of PFE. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

PFE stock traded up $0.27 during midday trading on Thursday, hitting $24.84. 36,770,116 shares of the company traded hands, compared to its average volume of 34,782,688. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50 day simple moving average of $24.82 and a 200-day simple moving average of $24.32. The stock has a market capitalization of $141.23 billion, a price-to-earnings ratio of 13.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent research reports. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. HSBC cut their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.